Role of Alzheimer's disease models in designing and testing experimental therapeutics

Alena Savonenko, Fiona M. Laird, Juan C Troncoso, Philip Chun Wong, Donald L. Price

Research output: Contribution to journalArticle

Abstract

The principal goals of investigating the models for Alzheimer's disease (AD) are to reproduce the amyloid/tau-related pathologies and the memory deficits occurring in patients. Recent models do allow crucial examinations of disease mechanisms and will be of great value in testing new therapeutic strategies including inhibition of BACE1 and β-secretase activities, modulators of γ-secretase and Aβ immunotherapies. Presently available mouse models can achieve a high degree of predictive validity for positive outcomes of experimental therapies, but they have been less successful in identifying potential adverse outcomes that can occur in human trials.

Original languageEnglish (US)
Pages (from-to)305-312
Number of pages8
JournalDrug Discovery Today: Disease Models
Volume2
Issue number4
DOIs
StatePublished - 2005

Fingerprint

Amyloid Precursor Protein Secretases
Alzheimer Disease
Investigational Therapies
Memory Disorders
Amyloid
Immunotherapy
Pathology
Therapeutics
Inhibition (Psychology)

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Role of Alzheimer's disease models in designing and testing experimental therapeutics. / Savonenko, Alena; Laird, Fiona M.; Troncoso, Juan C; Wong, Philip Chun; Price, Donald L.

In: Drug Discovery Today: Disease Models, Vol. 2, No. 4, 2005, p. 305-312.

Research output: Contribution to journalArticle

@article{70ad999ef998480b91f3cfc223e469a1,
title = "Role of Alzheimer's disease models in designing and testing experimental therapeutics",
abstract = "The principal goals of investigating the models for Alzheimer's disease (AD) are to reproduce the amyloid/tau-related pathologies and the memory deficits occurring in patients. Recent models do allow crucial examinations of disease mechanisms and will be of great value in testing new therapeutic strategies including inhibition of BACE1 and β-secretase activities, modulators of γ-secretase and Aβ immunotherapies. Presently available mouse models can achieve a high degree of predictive validity for positive outcomes of experimental therapies, but they have been less successful in identifying potential adverse outcomes that can occur in human trials.",
author = "Alena Savonenko and Laird, {Fiona M.} and Troncoso, {Juan C} and Wong, {Philip Chun} and Price, {Donald L.}",
year = "2005",
doi = "10.1016/j.ddmod.2005.11.006",
language = "English (US)",
volume = "2",
pages = "305--312",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Role of Alzheimer's disease models in designing and testing experimental therapeutics

AU - Savonenko, Alena

AU - Laird, Fiona M.

AU - Troncoso, Juan C

AU - Wong, Philip Chun

AU - Price, Donald L.

PY - 2005

Y1 - 2005

N2 - The principal goals of investigating the models for Alzheimer's disease (AD) are to reproduce the amyloid/tau-related pathologies and the memory deficits occurring in patients. Recent models do allow crucial examinations of disease mechanisms and will be of great value in testing new therapeutic strategies including inhibition of BACE1 and β-secretase activities, modulators of γ-secretase and Aβ immunotherapies. Presently available mouse models can achieve a high degree of predictive validity for positive outcomes of experimental therapies, but they have been less successful in identifying potential adverse outcomes that can occur in human trials.

AB - The principal goals of investigating the models for Alzheimer's disease (AD) are to reproduce the amyloid/tau-related pathologies and the memory deficits occurring in patients. Recent models do allow crucial examinations of disease mechanisms and will be of great value in testing new therapeutic strategies including inhibition of BACE1 and β-secretase activities, modulators of γ-secretase and Aβ immunotherapies. Presently available mouse models can achieve a high degree of predictive validity for positive outcomes of experimental therapies, but they have been less successful in identifying potential adverse outcomes that can occur in human trials.

UR - http://www.scopus.com/inward/record.url?scp=30444441141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444441141&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2005.11.006

DO - 10.1016/j.ddmod.2005.11.006

M3 - Article

AN - SCOPUS:30444441141

VL - 2

SP - 305

EP - 312

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

IS - 4

ER -